{"downloaded": true, "htmlmade": false, "full": {"id": "29867923", "source": "MED", "pmid": "29867923", "pmcid": "PMC5951114", "fullTextIdList": {"fullTextId": "PMC5951114"}, "doi": "10.3389/fimmu.2018.00834", "title": "Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.", "authorString": "Darlington PJ, Stopnicki B, Touil T, Doucet JS, Fawaz L, Roberts ME, Boivin MN, Arbour N, Freedman MS, Atkins HL, Bar-Or A.", "authorList": {"author": [{"fullName": "Darlington PJ", "firstName": "Peter J", "lastName": "Darlington", "initials": "PJ", "authorId": {"@type": "ORCID", "#text": "0000-0002-7976-9108"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Departments of Exercise Science and Biology, PERFORM Centre, Concordia University, Montreal, QC, Canada."}}}, {"fullName": "Stopnicki B", "firstName": "Brandon", "lastName": "Stopnicki", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Departments of Exercise Science and Biology, PERFORM Centre, Concordia University, Montreal, QC, Canada."}}}, {"fullName": "Touil T", "firstName": "Tarik", "lastName": "Touil", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Neuroimmunology Unit, McGill University and Montreal Neurological Institute, Montreal, QC, Canada."}}}, {"fullName": "Doucet JS", "firstName": "Jean-Sebastien", "lastName": "Doucet", "initials": "JS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Neuroimmunology Unit, McGill University and Montreal Neurological Institute, Montreal, QC, Canada."}}}, {"fullName": "Fawaz L", "firstName": "Lama", "lastName": "Fawaz", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Neuroimmunology Unit, McGill University and Montreal Neurological Institute, Montreal, QC, Canada."}}}, {"fullName": "Roberts ME", "firstName": "Morgan E", "lastName": "Roberts", "initials": "ME", "authorId": {"@type": "ORCID", "#text": "0000-0002-5850-7985"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Neuroimmunology Unit, McGill University and Montreal Neurological Institute, Montreal, QC, Canada."}}}, {"fullName": "Boivin MN", "firstName": "Marie-No\u00eblle", "lastName": "Boivin", "initials": "MN", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Neuroimmunology Unit, McGill University and Montreal Neurological Institute, Montreal, QC, Canada."}, {"affiliation": "Clinical Biological Imaging and Genetic Repository, McGill University, Montreal, QC, Canada."}]}}, {"fullName": "Arbour N", "firstName": "Nathalie", "lastName": "Arbour", "initials": "N", "authorId": {"@type": "ORCID", "#text": "0000-0002-3718-1584"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurosciences, Universit\u00e9 de Montr\u00e9al, Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CRCHUM), Montr\u00e9al, QC, Canada."}}}, {"fullName": "Freedman MS", "firstName": "Mark S", "lastName": "Freedman", "initials": "MS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada."}}}, {"fullName": "Atkins HL", "firstName": "Harold L", "lastName": "Atkins", "initials": "HL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Blood and Marrow Transplant Program, Ottawa General Hospital, Ottawa, ON, Canada."}}}, {"fullName": "Bar-Or A", "firstName": "Amit", "lastName": "Bar-Or", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Neuroimmunology Unit, McGill University and Montreal Neurological Institute, Montreal, QC, Canada."}, {"affiliation": "Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States."}]}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-3718-1584"}, {"@type": "ORCID", "#text": "0000-0002-5850-7985"}, {"@type": "ORCID", "#text": "0000-0002-7976-9108"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"volume": "9", "journalIssueId": "2647771", "dateOfPublication": "2018", "monthOfPublication": "0", "yearOfPublication": "2018", "printPublicationDate": "2018-01-01", "journal": {"title": "Frontiers in immunology", "ISOAbbreviation": "Front Immunol", "medlineAbbreviation": "Front Immunol", "NLMid": "101560960", "ISSN": "1664-3224", "ESSN": "1664-3224"}}, "pubYear": "2018", "pageInfo": "834", "abstractText": "In autoimmunity, the balance of different helper T (Th) cell subsets can influence the tissue damage caused by autoreactive T cells. Pro-inflammatory Th1 and Th17 T cells are implicated as mediators of several human autoimmune conditions such as multiple sclerosis (MS). Autologous hematopoietic stem cell transplantation (aHSCT) has been tested in phase 2 clinical trials for MS patients with aggressive disease. Abrogation of new clinical relapses and brain lesions can be seen after ablative aHSCT, accompanied by significant reductions in Th17, but not Th1, cell populations and activity. The cause of this selective decrease in Th17\u2009cell responses following ablative aHSCT is not completely understood. We identified an increase in the kinetics of natural killer (NK) cell reconstitution, relative to CD4<sup>+</sup> T cells, in MS patients post-aHSCT, resulting in an increased NK cell:CD4<sup>+</sup> T cell ratio that correlated with the degree of decrease in Th17 responses. <i>Ex vivo</i> removal of NK cells from post-aHSCT peripheral blood mononuclear cells resulted in higher Th17\u2009cell responses, indicating that NK cells can regulate Th17 activity. NK cells were also found to be cytotoxic to memory Th17\u2009cells, and this toxicity is mediated through NKG2D-dependent necrosis. Surprisingly, NK cells induced memory T cells to secrete more IL-17A. This was preceded by an early rise in T cell expression of <i>RORC</i> and <i>IL17A</i> mRNA, and could be blocked with neutralizing antibodies against CD58, a costimulatory receptor expressed on NK cells. Thus, NK cells provide initial co-stimulation that supports the induction of a Th17 response, followed by NKG2D-dependent cytotoxicity that limits these cells. Together these data suggest that rapid reconstitution of NK cells following aHSCT contribute to the suppression of the re-emergence of Th17\u2009cells. This highlights the importance of NK cells in shaping the reconstituting immune system following aHSCT in MS patients.", "affiliation": "Departments of Exercise Science and Biology, PERFORM Centre, Concordia University, Montreal, QC, Canada.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic-eCollection", "pubTypeList": {"pubType": ["Clinical Trial", "Research Support, Non-U.S. Gov't", "research-article", "Journal Article"]}, "grantsList": {"grant": {"agency": "CIHR", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Killer Cells, Natural", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Multiple Sclerosis, Relapsing-Remitting", "meshQualifierList": {"meshQualifier": [{"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Intercellular Signaling Peptides and Proteins", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Interleukin-17", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Cytokines", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "Y", "descriptorName": "Hematopoietic Stem Cell Transplantation"}, {"majorTopic_YN": "N", "descriptorName": "Transplantation, Autologous"}, {"majorTopic_YN": "N", "descriptorName": "Autoimmunity"}, {"majorTopic_YN": "N", "descriptorName": "Immunologic Memory"}, {"majorTopic_YN": "N", "descriptorName": "Gene Expression Regulation"}, {"majorTopic_YN": "N", "descriptorName": "Th17 Cells", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "GPI-Linked Proteins", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "CD58 Antigens", "meshQualifierList": {"meshQualifier": {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}}}]}, "keywordList": {"keyword": ["CD58", "Multiple sclerosis", "Natural killer cells", "AHSCT", "NKG2D", "Th17\u2009cells"]}, "chemicalList": {"chemical": [{"name": "ULBP2 protein, human", "registryNumber": "0"}, {"name": "Intercellular Signaling Peptides and Proteins", "registryNumber": "0"}, {"name": "Cytokines", "registryNumber": "0"}, {"name": "Interleukin-17", "registryNumber": "0"}, {"name": "IL17A protein, human", "registryNumber": "0"}, {"name": "GPI-Linked Proteins", "registryNumber": "0"}, {"name": "CD58 Antigens", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.3389/fimmu.2018.00834"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5951114"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5951114?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "12", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-06-14", "dateOfCreation": "2018-06-06", "firstIndexDate": "2018-06-06", "fullTextReceivedDate": "2020-07-09", "dateOfRevision": "2019-06-14", "electronicPublicationDate": "2018-05-07", "firstPublicationDate": "2018-05-07"}, "htmllinks": "https://europepmc.org/articles/PMC5951114", "abstract": "In autoimmunity, the balance of different helper T (Th) cell subsets can influence the tissue damage caused by autoreactive T cells. Pro-inflammatory Th1 and Th17 T cells are implicated as mediators of several human autoimmune conditions such as multiple sclerosis (MS). Autologous hematopoietic stem cell transplantation (aHSCT) has been tested in phase 2 clinical trials for MS patients with aggressive disease. Abrogation of new clinical relapses and brain lesions can be seen after ablative aHSCT, accompanied by significant reductions in Th17, but not Th1, cell populations and activity. The cause of this selective decrease in Th17\u2009cell responses following ablative aHSCT is not completely understood. We identified an increase in the kinetics of natural killer (NK) cell reconstitution, relative to CD4<sup>+</sup> T cells, in MS patients post-aHSCT, resulting in an increased NK cell:CD4<sup>+</sup> T cell ratio that correlated with the degree of decrease in Th17 responses. <i>Ex vivo</i> removal of NK cells from post-aHSCT peripheral blood mononuclear cells resulted in higher Th17\u2009cell responses, indicating that NK cells can regulate Th17 activity. NK cells were also found to be cytotoxic to memory Th17\u2009cells, and this toxicity is mediated through NKG2D-dependent necrosis. Surprisingly, NK cells induced memory T cells to secrete more IL-17A. This was preceded by an early rise in T cell expression of <i>RORC</i> and <i>IL17A</i> mRNA, and could be blocked with neutralizing antibodies against CD58, a costimulatory receptor expressed on NK cells. Thus, NK cells provide initial co-stimulation that supports the induction of a Th17 response, followed by NKG2D-dependent cytotoxicity that limits these cells. Together these data suggest that rapid reconstitution of NK cells following aHSCT contribute to the suppression of the re-emergence of Th17\u2009cells. This highlights the importance of NK cells in shaping the reconstituting immune system following aHSCT in MS patients.", "Keywords": ["CD58", "Multiple sclerosis", "Natural killer cells", "AHSCT", "NKG2D", "Th17\u2009cells"], "pdflinks": "https://europepmc.org/articles/PMC5951114?pdf=render", "journaltitle": "Frontiers in immunology", "authorinfo": ["Darlington PJ", "Stopnicki B", "Touil T", "Doucet JS", "Fawaz L", "Roberts ME", "Boivin MN", "Arbour N", "Freedman MS", "Atkins HL", "Bar-Or A"], "title": "Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis."}